-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CAR20.19.22 T-cells in T-Cell Lymphomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CAR20.19.22 T-cells in T-Cell Lymphomas Drug Details: Gene-modified cell therapy is under investigation for the...
-
Product Insights
T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) - Drugs In Development, 2023’, provides an overview of the T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
T-Cell Leukemia – Drugs In Development, 2023
Global Markets Direct’s, ‘T-Cell Leukemia - Drugs In Development, 2023’, provides an overview of the T-Cell Leukemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for T-Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Inducible T Cell Costimulator – Drugs In Development, 2023
Global Markets Direct’s Inducible T Cell Costimulator provides in depth analysis on Inducible T Cell Costimulator targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Inducible T Cell...
-
Product Insights
B And T Lymphocyte Attenuator – Drugs In Development, 2023
Global Markets Direct’s B And T Lymphocyte Attenuator provides in depth analysis on B And T Lymphocyte Attenuator targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in B...
-
Product Insights
Cutaneous T-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Cutaneous T-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Cutaneous T-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cutaneous T-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ponatinib Hydrochloride in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ponatinib Hydrochloride in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) Drug Details: Ponatinib (Iclusig)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RD-1302 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RD-1302 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) Drug Details: RD13-02 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Purinostat Mesylate in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Purinostat Mesylate in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) Drug Details: Purinostat mesylate...
-
Product Insights
Peripheral T-Cell Lymphomas (PTCL) – Drugs In Development, 2023
Global Markets Direct’s, ‘Peripheral T-Cell Lymphomas (PTCL) - Drugs In Development, 2023’, provides an overview of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...